These data serve as a foundation for further evaluation of cobolimab in multiple indications, including anti–PD-(L)1 refractory and relapsed advanced NSCLC (COSTAR Lung, NCT04655976), PD-1–naïve hepatocellular carcinoma (NCT03680508), and high-risk resectable melanoma (Neo-MEL-T, NCT04139902). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.